Melanoma is the most lethal skin tumor in large part because of a propensity for early metastasis. Good models of this most clinically relevant feature of melanoma are lacking. Here, we report the development of an in-vivo model of metastasis that relies on orthotopic injection of green fluorescent protein-tagged lines in immunodeficient mice, serial intravital imaging of tumor progression, and quantification of distant spread by two-photon laser scanning microscopy, immunohistochemistry, and real-time PCR analysis. Using this system, we report an assessment of the in-vivo growth and metastatic properties of 11 well-characterized human melanoma cell lines. A subset of lines showed rapid in-vivo growth with invasion of host vasculature and distant seeding of viscera in this system. The ability to form metastasis in vivo did not correlate with three-dimensional collagen invasion in vitro. Surprisingly, similar lines in terms of molecular genetic events differed markedly in their propensity to metastasize to distant organs such as brain and lung. In particular, two lines harboring B-RAF mutation and high levels of phosphorylated ERK and AKT were reproducibly unable to form tumors after orthotopic injection. Similarly, two previously identified RAS/RAF wildtype 'epithelial like' lines that do not have elevated phosphorylated ERK and AKT or express TWIST1 mRNA still showed a pronounced ability for orthotopic growth and metastatic spread. All the metastatic cell lines in this model showed increased NEDD9 expression, but NEDD9 lentiviral overexpression did not convey a metastatic phenotype on nonmetastatic cells. These data suggest that melanoma metastasis is a molecularly heterogeneous process that may not require epithelial-to-mesenchymal transition or ERK activation, although both may facilitate the process.
Introduction
A clinical hallmark of melanoma is a proclivity to early distant metastasis, even from primary tumors of small size. For example, in 5-15% of patients presenting with metastatic melanoma, no primary tumor can be found [1] [2] [3] [4] . The process of metastasis, the most lethal feature of melanoma, is not well understood. We believe this deficiency in our understanding largely stems from a lack of good model systems to study this complex multistep process. To date, the majority of studies on this topic have relied on tissue culture systems or tail vein injections of immunodeficient mice (reviewed in [5] [6] [7] [8] ). Although these systems have some experimental strength, they do not faithfully recapitulate the events that are involved in metastatic spread of autochthonous tumors. Thus, there is a need for in-vivo models that better mimic the human disease, in regards to tumor microenvironment and metastasis formation.
Human and murine skin differs in significant aspects, particularly in terms of melanocyte distribution. Melanocytes of human skin are predominantly located at the junction of epidermis and dermis with some melanocytes present in hair follicles, whereas in mice the melanocytes are predominantly within hair follicles or the interfollicular dermis, and are rarely present at the dermal/ epidermal junction [9, 10] . Important exceptions are the murine ear and tail, which share a comparable melanocyte distribution as in humans [10] . This is of importance considering the influence that the microenvironment plays in the maintenance of cellular homeostasis, and in the development of cancer. This fact, combined with studies showing enhanced metastases of human melanoma cell lines after subdermal implantation in nude mice ( [11, 12] and reviewed in [5] ), suggests that injection of human melanoma cells intradermally into the ear of severe combined immunodeficient (SCID) mice would constitute a more orthotopic model of human melanoma growth and metastasis than intravenous or subcutaneous injection. Importantly, this system also allows for noninvasive serial intravital imaging of tumors by multiphoton microscopy.
An identifiable oncogenic 'driver' event can be found in most human melanoma: B-RAF (approximately 60%), N-RAS (approximately 20%), or c-KIT (< 5%) mutation [13] [14] [15] [16] [17] [18] . We earlier characterized a panel of melanoma cell lines for N-RAS and B-RAF mutation status, ERK and AKT activation status, INK4a/ARF status, G1 checkpoint response, proliferation rates, and RNA expression profiles ( [19] and Table 1 ). We found that increased ERK and AKT activation correlated strongly with mutational status of RAS-RAF pathway members and showed that melanoma cell lines lacking N-RAS/B-RAF mutation had low ERK and AKT activity and decreased expression of ERK-regulated gene transcripts. Our analyses suggested the existence of an 'epithelial like' form of melanoma that is molecularly distinct from the more common form of RAS/RAF mutant melanoma and does not require ERK activation nor epithelial-to-mesenchymal transformation for progression. In this study, we extend the analysis of these well-characterized cell lines to include a study of metastatic propensity in an orthotopic xenograft model.
Metastasis is a multistep process that involves the concerted action of genes that regulate invasion of the surrounding stroma, migration towards and intravasation into the vasculature, survival in the circulation, extravasation, survival, and proliferation in the target organ [20] . A characteristic of metastasis in some systems is an epithelial to mesenchymal transition (EMT) [21, 22] . TWIST and NEDD9 are the two genes that have been recently linked to EMT and metastasis. TWIST has been shown to enhance intravasation and metastasis in different types of cancer [22, 23] , whereas NEDD9 was identified as a melanoma metastasis gene involved in the induction of the mesenchymal-type movement in melanoma cells [24, 25] . Moreover, we recently described the regulation of NEDD9 and metastasis by LKB1/STK11 in a mouse model of lung cancer and the deletion of LKB1 in human samples [26] .
Given the complexity of metastasis, it is important to generate experimental models in which most or all steps of the metastatic cascade are represented. In this study, we have characterized the ability of a well-characterized panel of cell lines to grow in vivo and metastasize using a novel orthotopic xenograft system. We injected green fluorescent protein (GFP)-expressing cells intradermally into the ears of nonobese diabetic (NOD)-SCID mice and used two-photon laser scanning microscopy for the noninvasive imaging of the skin to follow tumor cell fate in vivo in real time [27, 28] . In this way, we have shown that melanoma cell lines markedly differ in their ability to form tumors and metastasize. Importantly, in this model, metastasis was not generally correlated with features reported earlier [22, 23, [29] [30] [31] [32] to enhance metastatic spread including EMT, RAS/RAF mutation, TWIST1 expression, ERK activation, in-vitro proliferation rate, three-dimensional (3D) collagen invasion or adhesion. These data indicate that melanoma metastasis is a molecularly heterogeneous and complex process.
Methods
Cell culture, mutational analysis, and proliferation assays Human melanoma cell lines WM2664, A375, A2058, Mel505, RPMI8322, SK-MEL187, SK-MEL23, UACC257, SK-MEL24 and SK-MEL28, and 293FT cells were obtained from the sources detailed earlier and cultured as described earlier [33] . Genomic DNA was isolated using Genomic Tips kits (Qiagen, Valencia, California, USA), and the mutational status of C-KIT (exons 11, 13, and 17) was determined by direct sequencing of PCR amplification products as described in [16, 34] . B-RAF (exons 11 and 15) and N-RAS (codons 12, 13, and 61) mutational status were as described earlier [19] . We assessed in-vitro cell proliferation by crystal violet staining as described earlier [35] and Cell-Titer Glo luminescence 
Western blot analysis
Western blot assays were done on melanoma cell lysates in radioimmunoprecipitation assay buffer with protease inhibitors (Roche, Indianapolis, Indiana, USA) and phosphatase inhibitors (Calbiochem, San Diego, California, USA) as described earlier [36] . Primary antibodies used were: Twist-1 (H-81, Santa Cruz Biotechnology, Santa Cruz, California, USA), LKB-1 (gift from N. Bardeesi), NEDD9 (clone 2G9, gift from E. Pugacheva and E. Golemis), and actin as loading control (C-11, Santa Cruz Biotechnology). We used IRDye-conjugated secondary antibodies and imaged the membranes using an Odyssey infrared imaging system (LI-COR, Lincoln, Nebraska, USA).
DNA constructs, viral production, and infection of target cells
The pLentiLox 3.7 (pLL3.7) vector [37] that expresses GFP under a cytomegalovirus promoter was used. The production of lentiviruses in 293FT cells and infection of target cells were as described earlier [37] . For NEDD9 modulation, various short hairpin RNAs (shRNAs) targeting human NEDD9 were generated using the pLL3.7 vector and tested for their ability to inhibit NEDD9 protein expression by western blot. The most effective NEDD9 shRNA was used to inhibit NEDD9 expression in A375, A2058, and WM2664 cells, and a nonspecific shRNA was used as control. A GFP-NEDD9 lentiviral construct (gift from E. Pugacheva and E. Golemis, [38] ) was used to overexpress human NEDD9 in SK-MEL24, SK-MEL28, and SK-MEL187 cells using the pLL3.7 vector as control. Human melanoma cells were infected with the viral supernatant, and GFP + cells were isolated by flow cytometry as described earlier [33] .
Orthotopic tumor injections and intravital microscopy
Female NOD/SCID mice 6-8-weeks old were anesthetized with 2% isofluorane, and 5 Â 10 5 GFP-tagged tumor cells in 10 ml of Dulbecco's modified Eagle's medium were injected intradermally on the dorsal side of each ear using a 10 ml syringe with a 26-gauge needle. At least six to 16 injections per cell line were performed. For serial confocal imaging, mice were anesthetized with ketamine/ xylazine, and ear fur was removed using a commercially available chemical depilatory agent. Injected ears were imaged at 1, 2, 7, and 14 days posttumor injection, and additionally at the time of euthanasia: tumors of 1.3 cm diameter or 90 days after injection. Fluorescence in the ears was excited with 900 nm light from a Chameleon Ultra Ti-Sapphire pulsed laser (Coherent Inc., Santa Clara, California, USA) and imaged with a Zeiss LSM 510 NLO inverted two-photon laser scanning microscope (Zeiss, Thornwood, New York, USA) using 10 Â 0.3 numerical aperture (NA), 20 Â 0.5 NA, and 40Â1.2 NA (water immersion) objectives. Images were captured using a 12-bit cooled CCD camera (Hamamatsu). Dextran red (MW 75 000, Molecular Probes, Eugene, Oregon, USA) was injected through tail vein to image blood vessels and to help visualize intravasated tumor cells. All mice were housed and treated in accordance with protocols approved by the institutional care and use committees for animal research at the University of North Carolina.
Imaging of metastatic cells in organs
Mice were euthanized and organs were placed on a glass bottom chamber and imaged using the Zeiss LSM 510 NLO inverted two-photon laser scanning microscope with the Â10, Â20, and Â40 objectives. Images were captured using a Hamamatsu 12-bit cooled CCD camera. Brain, lungs, spleen, liver, and kidneys from all mice were analyzed. GFP-expressing cells were easily detected over the background autofluorescence present in all organs, which was used for anatomical detailing. The criteria for considering a cell GFP + included green emission using an excitation wavelength of 900 nm, without emission in the red spectra (excitation wavelength 543 nm), which would indicate autofluorescence as is reported in several tissues including lung macrophages [39] [40] [41] . To determine the sensitivity of this assay to detect human cells in murine tissues, we extracted RNA from a mix of mouse (3T3) and human (WM2664) cells at various ratios. Using this approach we were able to detect 64 human cells among 10 6 murine cells (approximately one in 16 000 cells). NEDD9 expression in indicated samples was determined by RT-PCR using the primers and probe described by Zheng and McKeown-Longo [43] and normalized to human b-actin values. Cycle threshold values were used to calculate fold change expression of NEDD9.
Results

Characterization of cell lines and in-vitro proliferation
For these studies, we chose a representative panel of human melanoma cell lines harboring either B-RAF mutation (UACC257, SK-MEL24, SK-MEL28, A2058, A375, WM2664) or 'wildtype (WT)' lines lacking RAS/ RAF mutation (PMWK, RPMI8322, Mel505, SK-MEL187, SK-MEL23) from a panel of earlier described melanoma cell lines [19] . We did not analyze N-RAS mutant lines as they are less frequent than either B-RAF mutant or RAS/ RAF WT lines, and we had earlier noted that N-RAS and B-RAF mutant lines are similar in terms of in-vitro growth, AKT/ERK activation, and gene expression. On the basis of the growing evidence that some melanomas harbor oncogenic C-KIT mutations [16, 17] , we further analyzed our entire panel of cell lines for activating C-KIT mutation.
No activating C-KIT mutations were detected in any of the 11 melanoma cell lines described in this or our earlier report [19] . Importantly, our prior analyses of these lines included extensive characterization of the tumor genomes, mRNA expression profiles, and protein expression. In particular, we showed that most of the WT cell lines express epithelial markers such as keratins and P/E cadherins, with decreased TWIST expression.
For intravital experiments, we stably expressed GFP in all cell lines using the lentiviral vector pLL3.7, and selected for the GFP+ cells by fluorescent activated cell sorter. We characterized the in-vitro proliferation rates of the lines for study over a 1-week period of culture. We noted heterogeneity among the cultures with regard to in-vitro growth, but generally B-RAF mutant lines exhibited more rapid growth than RAS/RAF WT lines ( Fig. 1a and Table 1 ). An exception was UACC257, a B-RAF mutant line that grew slowly in vitro. These differences in in-vitro growth rates may reflect intrinsic biologic features of the tumors from which these cells were derived, or reflect enhanced adaptation to experimental culture conditions ex vivo.
Characterization of in-vivo growth
To more physiologically analyze the ability of these cell lines to grow and form tumors, we designed an in-vivo model that relies on: (i) orthotopic intradermal injection of GFP-tagged cell lines into the ears of NOD-SCID mice, (ii) serial intravital imaging of tumor progression, and (iii) quantification of distant spread by two-photon laser scanning microscopy, immunohistochemistry (IHC) and RT-PCR analysis. We performed a time-course analysis of tumor cell growth in vivo of the 11 melanoma cell lines by imaging the ears of the melanoma cellinjected mice at 1, 2, 7, 14 days and experiment termination. We could easily detect GFP + cells in the ear at 24 h postinjection, and were able to observe increased cell numbers 48 h and 1 week postinjection, at times when no tumors were detectable by palpation ( Fig. 2a ). Using dextran red to stain the vasculature, intravasated tumor cells could be detected in some cases by 2 weeks postinjection ( Fig. 2b and c) . These seemed as round individual GFP + cells inside the blood vessels. In all the animals analyzed, we never detected lymph node metastasis. These observations suggest that this technique is suitable for the follow-up of tumor growth even at a single cell level, and is sensitive enough to detect hematogenous spread.
As was the case with in-vitro proliferation, we noted marked heterogeneity among melanoma cell lines with regard to their ability to grow in this in-vivo system. Although some cell lines were noted to grow well in vivo (SK-MEL28, SK-MEL187, A375, WM2664, Mel505, and RPMI8322), others were unable to form tumors in the ears of NOD-SCID mice (UACC257, SK-MEL24, SK-MEL23, PMWK; Table 1 , Fig. 1b ). Using this in-vivo model of tumor growth, we observed no correlation between in-vitro and in-vivo growth (data not shown), suggesting the importance of the in-vivo model in the characterization of tumor cell lines. On the basis of our prior and present analysis of these cell lines [19] , the ability to form orthotopic tumors did not correlate with known molecular features of the cell lines ( Fig. 1b and c, Table 1 ). For example, a few WT lines harboring low levels of pERK and pAKT (SK-MEL187, Mel505, RPMI8322) grew in-vivo and or faster than some B-RAF mutant cell lines that have increased pERK and pAKT levels (SK-MEL28, A2058, A375, WM2664; Fig. 1b ). Similarly, growth in this assay did not correlate with INK4a/ ARF mutational status, expression of pAKT, TWIST1 expression, or an 'EMT phenotype' (indicated by expression of keratins, TWIST and P/E-cadherins), despite literature suggesting roles for these genetic events in tumor progression and invasion [22, 23, [44] [45] [46] [47] . Although our sample is too small to exclude the possibility that these genetic events enhance tumor growth, these data show that none of these molecular features is strictly required for local orthotopic growth of melanoma cell lines in immunodeficient mice.
Detection of metastasis
To determine the relationship between primary orthotopic growth and distant spread, tumor-bearing mice were analyzed for metastasis. Mice were sacrificed at 90 days postinjection or when primary ear tumors reached 1.3 cm in size, and organs were harvested for analysis. Fresh organs were imaged by two-photon laser scanning microscopy, and formalin-fixed paraffin-embedded organs were analyzed by IHC for GFP. In addition, RT-PCR for human b-actin mRNA was used to confirm the presence of human melanoma cells in the studied organs. While no metastases were observed macroscopically in any distant organ, using two-photon laser scanning imaging, we detected small GFP + foci in the lungs and brains of mice harboring tumors derived from WM2664, A2058, A375, and RPMI8322 cells, and in the brains of Mel505 tumor-bearing mice ( Table 2 , Fig. 3 ). RT-PCR amplification of human b-actin mRNA ( Table 2) confirmed the presence of metastatic spread in lungs and brains. Moreover, by RT-PCR, we detected the presence of human cells in the lungs and brains of tumor-bearing mice that did not show signs of GFP + cells by twophoton laser scanning microscopy (Table 2 ), suggesting RT-PCR amplification is more sensitive to detect rare, distantly spread cells (e.g. identifying a single human cell approximately 16 000 mouse cells, see Methods). Importantly, however, the physiological significance of rare tumor cells detected by two-photon microscopy or RT-PCR is unknown, and could merely represent intravascular circulating tumor cells rather than nascent metastatic foci.
We further confirmed the presence of tumor foci in lungs of A2058 and WM2664 tumor-bearing mice by IHC staining for GFP ( Fig. 4 ), but we were unable to detect GFP + cells in the lungs of A375 or RPMI8322 tumorbearing mice by this method (Fig. 4 and data not shown). We believe this shows an increased sensitivity of twophoton imaging of whole organs over commonly employed techniques of serial paraffin sectioning with IHC analysis. Three animals showed lymph node enlargement, but metastatic tumor was not observed in these nodes suggesting enlargement reflected a reactive process. A comprehensive investigation of lymph node metastasis was not performed in the absence of nodal enlargement. Finally, no melanoma cells were observed in the liver, spleen, or kidney of any tumor-bearing mice by twophoton, IHC, or RT-PCR ( Fig. 3 , Table 2 and data not shown). In summary, these data suggest a predilection of certain of these melanoma cell lines for metastatic spread to brain and lung, but not other organs tested.
Gene expression analysis
We sought to determine whether tumor molecular genetics or gene expression correlated with metastatic spread in this system. As with primary tumor growth, no correlation was noted between distant spread and RAS/RAF mutation, INK4a/ARF nor p53 status, expression of pAKT nor pERK, TWIST1 expression, nor expression of markers associated with EMT, particularly, the WT cell lines Mel505 and RPMI8322, which have metastatic properties in the absence of RAS-RAF mutations, express keratins, P/E-cadherin, and CD24 [19] . We have earlier analyzed genome-wide mRNA expression of these lines by high-density microarray analysis [19] , and we also performed several types of supervised analyses using SAM [48] to compare mRNA expression with tumor growth or metastasis. Although we performed independent SAM analysis by cell line growth, cell line metastasis to any organ, cell line metastasis to lung, and cell line metastasis to brain, no robust gene signature with low false-discovery rate could be identified that correlated with local growth or metastatic spread 
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Detection of metastatic cells in whole organs. Representative two-photon images of tumors and organs of mice injected with the different human melanoma cell lines at end-point (when tumors reached 1.3 cm diameter or 90 days postinjection). SK-MEL28 cells form rapidly growing tumors, but show no signs of metastasis in any organs. WM2664 and A2058 cells form slow-growing tumors that metastasize to lungs and brain. SK-MEL24 cells were not able to form overt tumors and did not give rise to metastasis in any organs, but cells were still present in the ear 90 days after injection. Note anatomical detailing of organs by autofluorescence. Scale bar: 100 mm.
in any of these analyses. Although it is worth noting that 11 samples provide only limited statistical power for supervised genome-wide expression analysis, these data suggest heterogeneity of gene expression among cell lines capable of distant spread in this system.
Melanoma metastasis protein expression
We analyzed the expression of metastasis genes in this system. Given previous findings [22] [23] [24] [25] [26] , we studied TWIST, LKB-1, and NEDD9 protein expression in our panel of cell lines. Although no correlation was observed between TWIST or LKB-1 expression in vitro and tumorigenesis or metastasis in vivo, all the cell lines that were able to metastasize in vivo expressed NEDD9 protein (Fig. 5a ), consistent with earlier reports of NEDD9 being involved in melanoma metastasis [24] . On the basis of these data, we further evaluated the role of NEDD9 in metastasis formation in our model.
For this purpose, we overexpressed GFP-NEDD9 using a lentiviral construct [38] in cells that do not express NEDD9 and do not metastasize in our model (SK-MEL24, SK-MEL28 and SK-MEL187). Conversely, we inhibited NEDD9 expression in cells that are metastaic in our model (A375, A2058 and WM2664) using a lentiviral shRNA system (pLL3.7). We confirmed overexpression or downregulation of NEDD9 protein by western blot and RT-PCR ( Fig. 5b and Supplementary Figs 1 and 2, Table 1 , Supplementarty digital content https://genome.unc.edu/pubsup/melanomaresearch/rozenberg/). We then analyzed the effects of NEDD9 modulation on cell proliferation, cell adhesion, and cell invasion into 3D collagen in vitro ( Supplementary Fig. 3 , Supplementarty digital content https://genome.unc.edu/pubsup/melanomaresearch/ rozenberg/ and data not shown). Inconsistent effects of NEDD9 overexpression and knockdown were noted in vitro ( Supplementary Fig. 3 , Supplementarty digital content 
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Immunohistochemical (IHC) detection of green fluorescent protein (GFP) metastasis in lungs. Representative images of paraffin sections of tumors, lungs, and brains of mice injected with the different human melanoma cell lines at endpoint (when tumors reached 1.3 cm diameter or after 90 days). SK-MEL28 tumors stained positively for GFP (brown), but no GFP staining was observed in any organs from these mice by IHC. WM2664 and A2058 tumors and lungs were positive for GFP, confirming the two-photon data. All other organs were GFP negative. Scale bar: 200 mm.
https://genome.unc.edu/pubsup/melanomaresearch/rozenberg/), consistent with prior reports of NEDD9 enhancing and reducing in-vitro proliferation and regulating cell cycle progression (reviewed in [49, 50] ). In accord with results from Kim et al. [24] , NEDD9 downregulation in A2058 cells abrogated tumor growth in vivo, but did not affect tumor growth nor metastasis in two other RAF-mutant cell lines (A375 and WM2664, data not shown). Using both the orthotopic intradermal ear injection model and the 3D collagen invasion assay, we found that overexpression of NEDD9 in SK-MEL28, SK-MEL24, and SK-MEL187 cells was not sufficient to affect tumor growth nor to induce metastasis. Although the correlation of NEDD9 expression and results of NEDD9 knockdown in A2058 cells are consistent with an important role of this gene in melanoma metastasis as reported [24] , our data suggest that transient knockdown or overexpression of this gene is not universally sufficient to modulate melanoma metastasis.
Discussion
In this study, we have expanded our earlier analysis and characterization of a panel of human melanoma cell lines [19] using an in-vivo model of melanoma metastasis in which we injected GFP-tagged human melanoma cells intradermally into the ears of NOD-SCID mice. With this model, we were able to detect orthotopically growing single GFP + cells as early as 24 h postinjection, and were also able to observe intravasated GFP + cells in the vasculature at 2 weeks after injection. We found that several, but not all of the 11 human melanoma cell lines tested were able to grow rapidly in vivo, invade the vasculature, and form distant metastasis in the brains and lungs of NOD-SCID mice. We could detect metastatic foci in lungs and brains by two-photon laser scanning microscopy and confirmed these results through IHC and RT-PCR-based methods. We noted that two-photon imaging was more sensitive than IHC, but less sensitive than RT-PCR for detecting tumor cells in a distant organ. Hematogenous spread in this system was observed as micrometastases. It is possible that these tumor deposits were unable to form macrometastases because of some biological limit to growth, but more likely, we believe this observation reflects the fact that most mice had to be sacrificed because of growth of the primary ear tumor at a time before macrometastases could form. Possible means to overcome this issue might be to inject a smaller number of cells intradermally, or to resect the primary tumor after some initial period of growth.
Approximately 80% of metastatic melanomas harbor mutually exclusive activating mutations of either N-RAS or B-RAF (reviewed in [51] ). These lesions lead to activation of the RAF/MEK/ERK/MAPK pathway, which in turn controls the transcription of hundreds to thousands of genes related to cellular proliferation, survival, and motility [19] . There is extensive literature proposing ERK activation [29, 52] , RAS/RAF mutation [30, 31] , TWIST1 expression [23] , NEDD9 expression [24] , and EMT [21, 22, 53] as facilitators of metastasis, mainly for their roles in modulating cell-cell contacts, cell motility, cell adhesion, and inducing an invasive phenotype [32] . In our earlier study, we found increased ERK activation and TWIST1 expression in most RAS/RAF mutant melanoma cell lines when compared with epithelial-like cell lines (which express keratins and P/E cadherins) and normal human melanocytes [19] . As some WT lines showed rapid metastasis in this system, our results suggest that RAS/ RAF mutations, ERK activation, and expression of transcripts associated with EMT are not strictly required for metastasis, although these features may possibly facilitate the process. Our results are also consistent with the finding that epithelial markers keratin 18 and CD24 expression do not correlate with improved univariate survival in a tissue microarray data set [19] . It is important to note, however, that EMT has been reported to be a reversible process, and therefore we cannot exclude the possibility that this occurs in vivo to facilitate metastasis even in the WT lines, despite their in-vitro patterns of gene expression.
In summary, we describe an orthotopic melanoma mouse model for the study of early events contributing to the development of melanoma from human cell lines. Using this model, we describe the propensity of several commonly studied RAF-mutant and WT human melanoma cell lines to grow locally and spread distantly when injected orthotopically, and observe a correlation of NEDD9 expression with this process. The observed differences in growth and metastasis did not correlate with any of the other characterized molecular genetic features of the cell lines including several candidate genes thought to be involved in melanoma metastasis. Moreover, the ability to form metastasis in vivo did not correlate with 3D collagen invasion in vitro. One possible explanation for the poor correlation between assays is the lack of other stromal components, including cells such as fibroblasts and keratinocytes in the in-vitro assay. Although the hetero-geneity and small number of cell lines analyzed in our sample prevents us from drawing definitive conclusions about the relative role of these processes generally in melanoma spread, we consider it remarkable that certain WT melanoma cell lines without ERK activation or expression of transcripts associated with EMT showed rapid hematogenous spread to the brain and lung after orthotopic injection. Therefore, our study suggests that melanoma metastasis is a complex and heterogeneous process in vivo.
